Difference between revisions of "Carmustine"

From Dog
 
Line 3: Line 3:
 
Carmustine, similar in activity to [[lomustine]], is a mustard gas-related β-chloro-nitrosourea alkylating agent which crosslinks DNA and prevents its replication.
 
Carmustine, similar in activity to [[lomustine]], is a mustard gas-related β-chloro-nitrosourea alkylating agent which crosslinks DNA and prevents its replication.
  
It is usually administered as an adjunct drug in combination with [[cisplatin]]<ref>Wright KC ''et al'' (1987) Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs. ''Chemotherapy'' '''33(6)''':437-444</ref>, [[vincristine]] and [[prednisolone]].
+
It is usually administered as an adjunct drug in combination with [[cisplatin]]<ref>Wright KC ''et al'' (1987) Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs. ''Chemotherapy'' '''33(6)''':437-444</ref>, [[vincristine]] and [[prednisolone]]. A new formulation with carmustine made available as a lipid nanoemulsion has also shown benefit<ref>Lucas SR ''et al'' (2013) Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma. ''Vet Comp Oncol'' [http://www.ncbi.nlm.nih.gov/pubmed/23615221 Apr 25]</ref>.
  
 
Carmustine has also been compounded into a local, sustained-release injectable viscous gel for intralesional treatment of oral [[melanoma]]<ref>Kitchell BE ''et al'' (1994) Intralesional implant for treatment of primary oral malignant melanoma in dogs. ''J Am Vet Med Assoc'' '''204(2)''':229-236</ref>.
 
Carmustine has also been compounded into a local, sustained-release injectable viscous gel for intralesional treatment of oral [[melanoma]]<ref>Kitchell BE ''et al'' (1994) Intralesional implant for treatment of primary oral malignant melanoma in dogs. ''J Am Vet Med Assoc'' '''204(2)''':229-236</ref>.

Latest revision as of 06:26, 29 April 2013

Carmustine is a chemotherapy drug used primarily as an adjunct in treatment of lymphoma.

Carmustine, similar in activity to lomustine, is a mustard gas-related β-chloro-nitrosourea alkylating agent which crosslinks DNA and prevents its replication.

It is usually administered as an adjunct drug in combination with cisplatin[1], vincristine and prednisolone. A new formulation with carmustine made available as a lipid nanoemulsion has also shown benefit[2].

Carmustine has also been compounded into a local, sustained-release injectable viscous gel for intralesional treatment of oral melanoma[3].

Marked neutropenia is frequently observed following administration of this drug[4].

References

  1. Wright KC et al (1987) Experimental combination chemotherapy: intracarotid versus intravenous administration of aziridinylbenzoquinone, BCNU, and cisplatin in dogs. Chemotherapy 33(6):437-444
  2. Lucas SR et al (2013) Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma. Vet Comp Oncol Apr 25
  3. Kitchell BE et al (1994) Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 204(2):229-236
  4. Ricci Lucas SR et al (2004) Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma. J Am Anim Hosp Assoc 40(4):292-299